Sarah Cannon Research Institute, LLC

Nashville, Tennessee 37203

2 studies enrolling now · 9 studies all time

What they study most

Acute Graft-versus-host Disease, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Advanced Solid Tumors, Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Metastatic Castrate Resistant Prostate Cancer (mCRPC), NSCLC (Advanced Non-small Cell Lung Cancer), Non-small-cell Lung Cancer, Solid Tumor, Adult, Solid Tumors, Transitional Cell Carcinoma of the Bladder

Studies at this site

• A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations — Recruiting now
• First In Human Study of CX-2051 in Advanced Solid Tumors — Recruiting now
• A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). — Running, not enrolling
• Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects — Stopped early
• A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors — Stopped early
• Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) — Status unconfirmed
• Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors — Completed
• Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC — Completed
• Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer — Completed